Molecular characteristics and pathways of avastin for the treatment of glioblastoma multiforme

Neurosurgery Clinics of North America

Volumn 23, Issue 3, 2012, Pages 417-427

  Spasic, Marko ^a   Chow, Frances ^a   Tu, Claire ^a   Nagasawa, Daniel T ^a   Yang, Isaac ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Avastin; Bevacizumab; Chemotherapy; Glioblastoma; VEGF

Indexed keywords

BEVACIZUMAB; IRINOTECAN; TOPOTECAN; VASCULOTROPIN;

BLOOD VESSEL PERMEABILITY; BRAIN HEMORRHAGE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RESISTANCE; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863009497     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.05.002     Document Type: Review

References (103)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996.
2. Shibuya M. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor. FEBS J 2009, 276(17):4636-4643.
3. Brem S., Cotran R., Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 1972, 48(2):347-356.
4. Bello L., Giussani C., Carrabba G., et al. Angiogenesis and invasion in gliomas. Cancer Treat Res 2004, 117:263-284.
5. Ballman K.V., Buckner J.C., Brown P.D., et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 2007, 9(1):29-38.
6. Lamborn K.R., Yung W.K., Chang S.M., et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008, 10(2):162-170.
7. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13(4):1253-1259.
8. Kreisl T.N., Kim L., Moore K., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27(5):740-745.
9. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342.
10. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25(12):1539-1544.
11. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
12. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357(26):2666-2676.
13. Miles D.W., Chan A., Dirix L.Y., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28(20):3239-3247.
14. O'Shaughnessy J.A., Brufsky A.M. RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer. Clin Breast Cancer 2008, 8(4):370-373.
15. Reardon D.A., Desjardins A., Rich J.N., et al. The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol 2008, 9(1):1-22.
16. Desjardins A., Reardon D.A., Herndon J.E., et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008, 14(21):7068-7073.
17. Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27(28):4733-4740.
18. Vredenburgh J.J., Desjardins A., JE Herndon J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25(30):4722-4729.
19. Wong E.T., Gautam S., Malchow C., et al. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw 2011, 9(4):403-407.
20. Cloughesy T., Prados M.D., Wen P.Y., et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on a 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 2008, 26. ASCO Annual Meeting 2010.
21. Wilkerson J., Fojo T. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival. Cancer J 2009, 15(5):379-385.
22. Rubenstein J.L., Kim J., Ozawa T., et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000, 2(4):306-314.
23. Grothey A., Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009, 6(9):507-518.
24. Rapisarda A., Hollingshead M., Uranchimeg B., et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 2009, 8(7):1867-1877.
25. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(21):1182-1186.
26. Ellis L.M., Hicklin D.J. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 2008, 14(20):6371-6375.
27. Keunen O., Johansson M., Oudin A., et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 2011, 108(9):3749-3754.
28. Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 2008, 41(4):278-286.
29. Brown L.F., Yeo K.T., Berse B., et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 1992, 176(5):1375-1379.
30. Dvorak H.F., Sioussat T.M., Brown L.F., et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991, 174(5):1275-1278.
31. Armulik A., Genove G., Mae M., et al. Pericytes regulate the blood-brain barrier. Nature 2010, 468(7323):557-561.
32. Inai T., Mancuso M., Hashizume H., et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004, 165(1):35-52.
33. Abramsson A., Berlin O., Papayan H., et al. Analysis of mural cell recruitment to tumor vessels. Circulation 2002, 105(1):112-117.
34. Morikawa S., Baluk P., Kaidoh T., et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002, 160(3):985-1000.
35. Rosso L., Brock C.S., Gallo J.M., et al. A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res 2009, 69(1):120-127.
36. Yancopoulos G.D., Davis S., Gale N.W., et al. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407(6801):242-248.
37. Pajusola K., Aprelikova O., Armstrong E., et al. Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts. Oncogene 1993, 8(11):2931-2937.
38. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23(5):1011-1027.
39. Brock T.A., Dvorak H.F., Senger D.R. Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. Am J Pathol 1991, 138(1):213-221.
40. Antonetti D.A., Barber A.J., Hollinger L.A., et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999, 274(33):23463-23467.
41. Papadopoulos M.C., Saadoun S., Davies D.C., et al. Emerging molecular mechanisms of brain tumour oedema. Br J Neurosurg 2001, 15(2):101-108.
42. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473(7347):298-307.
43. Dvorak H.F., Brown L.F., Detmar M., et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146(5):1029-1039.
44. Kohn S., Nagy J.A., Dvorak H.F., et al. Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. Lab Invest 1992, 67(5):596-607.
45. Qu H., Nagy J.A., Senger D.R., et al. Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium. J Histochem Cytochem 1995, 43(4):381-389.
46. Kunkel P., Ulbricht U., Bohlen P., et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001, 61(18):6624-6628.
47. Plate K.H., Breier G., Weich H.A., et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992, 359(6398):845-848.
48. Goldberg M.A., Schneider T.J. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 1994, 269(6):4355-4359.
49. Korkolopoulou P., Perdiki M., Thymara I., et al. Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX. Hum Pathol 2007, 38(4):629-638.
50. Giatromanolaki A., Koukourakis M.I., Sivridis E., et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001, 61(21):7992-7998.
51. Underwood J.L., Murphy C.G., Chen J., et al. Glucocorticoids regulate transendothelial fluid flow resistance and formation of intercellular junctions. Am J Physiol 1999, 277(2 Pt 1):C330-C342.
52. Ellingson B.M., Cloughesy T.F., Lai A., et al. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011, 13(4):401-409.
53. Chamberlain M.C. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2009, 72(8):772-773. [author reply: 773-4].
54. Pope W.B., Lai A., Nghiemphu P., et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006, 66(8):1258-1260.
55. Ananthnarayan S., Bahng J., Roring J., et al. Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 2008, 88(3):339-347.
56. Ellingson B.M., Cloughesy T.F., Lai A., et al. Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. J Neurooncol 2011, 105:91-101.
57. Macdonald D.R., Cascino T.L., Schold S.C., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8(7):1277-1280.
58. Vos M.J., Uitdehaag B.M., Barkhof F., et al. Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology 2003, 60(5):826-830.
59. Zhou Y.H., Tan F., Hess K.R., et al. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 2003, 9(9):3369-3375.
60. Chaudhry I.H., O'Donovan D.G., Brenchley P.E., et al. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 2001, 39(4):409-415.
61. Dickson P.V., Hamner J.B., Sims T.L., et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007, 13(13):3942-3950.
62. Howe F.A., Barton S.J., Cudlip S.A., et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003, 49(2):223-232.
63. Holash J., Maisonpierre P.C., Compton D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284(5422):1994-1998.
64. Leenders W.P., Kusters B., Verrijp K., et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 2004, 10(18 Pt 1):6222-6230.
65. Claes A., Gambarota G., Hamans B., et al. Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment. Int J Cancer 2008, 122(9):1981-1986.
66. de Groot J.F., Fuller G., Kumar A.J., et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010, 12(3):233-242.
67. Sakariassen P.O., Prestegarden L., Wang J., et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S A 2006, 103(44):16466-16471.
68. Hentschel S.J., Lang F.F. Current surgical management of glioblastoma. Cancer J 2003, 9(2):113-125.
69. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307(5706):58-62.
70. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. In: World Federation of Neuro-Oncology Meeting. 2005 May 5-8; Edinburgh, United Kingdom; 2005. p. 91.
71. Hockel M., Schlenger K., Aral B., et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996, 56(19):4509-4515.
72. Rose S.D., Aghi M.K. Mechanisms of evasion to antiangiogenic therapy in glioblastoma. Clin Neurosurg 2010, 57:123-128.
73. Tille J.C., Wang X., Lipson K.E., et al. Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C(deltaNdeltaC)- and VEGF-A-induced angiogenesis in vitro. Exp Cell Res 2003, 285(2):286-298.
74. Kadambi A., Mouta Carreira C., Yun C.O., et al. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res 2001, 61(6):2404-2408.
75. Detmar M., Brown L.F., Schon M.P., et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998, 111(1):1-6.
76. Larcher F., Murillas R., Bolontrade M., et al. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 1998, 17(3):303-311.
77. Thurston G., Suri C., Smith K., et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999, 286(5449):2511-2514.
78. Suri C., McClain J., Thurston G., et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998, 282(5388):468-471.
79. Scharpfenecker M., Fiedler U., Reiss Y., et al. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005, 118(Pt 4):771-780.
80. Gale N.W., Dominguez M.G., Noguera I., et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A 2004, 101(45):15949-15954.
81. Li J.L., Sainson R.C., Shi W., et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 2007, 67(23):11244-11253.
82. Mailhos C., Modlich U., Lewis J., et al. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 2001, 69(2-3):135-144.
83. Patel N.S., Li J.L., Generali D., et al. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 2005, 65(19):8690-8697.
84. Noguera-Troise I., Daly C., Papadopoulos N.J., et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006, 444(7122):1032-1037.
85. Liu Z.J., Shirakawa T., Li Y., et al. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 2003, 23(1):14-25.
86. Real C., Remedio L., Caiado F., et al. Bone marrow-derived endothelial progenitors expressing Delta-like 4 (Dll4) regulate tumor angiogenesis. PLoS One 2011, 6(4):e18323.
87. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11(1):83-95.
88. Uhrbom L., Hesselager G., Nister M., et al. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res 1998, 58(23):5275-5279.
89. Dai C., Celestino J.C., Okada Y., et al. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 2001, 15(15):1913-1925.
90. Muller Y.A., Li B., Christinger H.W., et al. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci U S A 1997, 94(14):7192-7197.
91. Homsi J., Daud A.I. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007, 14(3):285-294.
92. Timke C., Zieher H., Roth A., et al. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 2008, 14(7):2210-2219.
93. Clark A.J., Butowski N.A., Chang S.M., et al. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg 2011, 114(6):1609-1616.
94. Kumar I., Staton C.A., Cross S.S., et al. Angiogenesis, vascular endothelial growth factor and its receptors in human surgical wounds. Br J Surg 2009, 96(12):1484-1491.
95. Bose D., Meric-Bernstam F., Hofstetter W., et al. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 2010, 11(4):373-382.
96. Lu J.F., Bruno R., Eppler S., et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008, 62(5):779-786.
97. Sugrue M., Bauman A., Jones F., et al. Clinical examination is an inaccurate predictor of intraabdominal pressure. World J Surg 2002, 26(12):1428-1431.
98. Gutin P.H., Iwamoto F.M., Beal K., et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009, 75(1):156-163.
99. Lai A., Tran A., Nghiemphu P.L., et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011, 29(2):142-148.
100. Raizer J.J., Grimm S., Chamberlain M.C., et al. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 2010, 116(22):5297-5305.
101. Khasraw M., Holodny A., Goldlust S.A., et al. Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. Ann Oncol 2012, 23(2):458-463.
102. Yang R., Thomas G.R., Bunting S., et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 1996, 27(6):838-844.
103. Nalluri S.R., Chu D., Keresztes R., et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008, 300(19):2277-2285.